Robert Davis - Intra Cellular Insider

Intra Cellular Therapies Inc -- USA Stock  

USD 22.50  0.27  1.21%

Senior Vice President and Chief Scientific Officer

Mr. Robert E. Davis is Ph.D., is Senior Vice President and Chief Scientific Officer of the Company. He previously served as President and CEO of 3D Pharmaceutical Consultants, providing consulting services to the Company from December 2005 to November 2015. From December 2000 until November 2005, Dr. Davis served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. From January 1994 until October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company focused on the design and development of drug therapies for mitochondrial diseases, serving at various times as its President, Chief Executive Officer and Chief Scientific Officer. Earlier, Dr. Davis held various positions at ParkeDavis Pharmaceutical Research, WarnerLambert. Earlier in his career, he participated in the discovery and development of Cognex, the first drug approved for treating Alzheimers disease, Neurontin, the first drug approved for treating neuropathic pain, and Nuplazid, a potential new treatment for psychosis associated with Parkinson disease
Age: 65  President Since 2015  Ph.D    
Davis received his B.S., M.S and Ph.D in Psychobiology from the University of Illinois.

Robert Davis Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (14.94) % which means that it has lost $14.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (23.56) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 6 records


Erez FeigeVascular Biogenics Ltd
Eyal BreitbartVascular Biogenics Ltd
Adam BuckleyVBI Vaccines Inc
Yael CohenVascular Biogenics Ltd
Stephanie HallerDimension Therapeutics Inc
Athena KartsaklisVBI Vaccines Inc

Entity Summary

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. Intra-Cellular Therapies, Inc. is headquartered in New York, New York. Intra Cellular operates under Biotechnology classification in USA and traded on NASDAQ. It employs 49 people.Intra Cellular Therapies Inc (ITCI) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 49 people. Intra Cellular is listed under Pharmaceutical Products category by Fama And French industry classification.

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Intra Cellular Therapies Inc to your portfolio

Top Management

Intra Cellular Thera Leadership Team
Lawrence Wennogle, President, Ph.D
Christopher Alafi, Director
Michael Rawlins, Director
Robert Nostrand, Director
Richard Lerner, Director
Robert Davis, President, Ph.D
Allen Fienberg, Founder, Ph.D
Michael Halstead, SVP
Sharon Mates, Chairman, Ph.D
Andrew Satlin, President
Juan Sanchez, President
Rory Riggs, Director, MBA
Joel Marcus, Director
Kimberly Vanover, VP, Ph.D
Lawrence Hineline, President, CPA

Stock Performance

Intra Cellular Performance Indicators